Yusuke Nakamura to Sarcoma, Synovial
This is a "connection" page, showing publications Yusuke Nakamura has written about Sarcoma, Synovial.
Connection Strength
1.239
-
Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005 Sep 15; 24(41):6201-12.
Score: 0.253
-
Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas. Oncogene. 2004 Jul 15; 23(32):5551-7.
Score: 0.233
-
FZD10-targeted a-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. Cancer Sci. 2022 Feb; 113(2):721-732.
Score: 0.195
-
a-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018 Jul; 109(7):2302-2309.
Score: 0.153
-
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 08; 18(1):646.
Score: 0.153
-
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008 Feb; 99(2):432-40.
Score: 0.075
-
Molecular target therapy for synovial sarcoma. Future Oncol. 2005 Dec; 1(6):805-12.
Score: 0.064
-
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005 Apr 01; 11(7):2702-12.
Score: 0.061
-
Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 2002 Oct 15; 62(20):5859-66.
Score: 0.052